Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Panbela Therapeutics Inc. PBLA

Healthcare  —  Biotechnology
0.01 0.00 0.00% as of 24 Sep
Market cap
$3.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Panbela Therapeutics Inc. (PBLA) Business Profile

Updated before January 2025

Company Overview

Panbela Therapeutics Inc. (PBLA) is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for the treatment of cancer and other diseases. Founded in 2011 and headquartered in Waconia, Minnesota, Panbela has focused its efforts on addressing unmet medical needs in oncology. The company is led by a team of experienced professionals in the pharmaceutical and biotechnology industries. Key leadership includes Dr. Jennifer K. Simpson, who serves as the President and Chief Executive Officer, bringing extensive expertise in oncology drug development and commercialization. The company’s mission is to improve the lives of patients by advancing novel therapeutic solutions.

Core Business Segments

Panbela Therapeutics operates primarily in the oncology sector, with a focus on developing small-molecule therapeutics. The company’s core business segments include:

1. Oncology Drug Development

Panbela’s flagship product candidate is SBP-101, a proprietary polyamine metabolic inhibitor. SBP-101 is being developed for the treatment of pancreatic cancer and other solid tumors. The drug works by targeting the metabolic pathways essential for tumor growth, offering a novel approach to cancer treatment. SBP-101 has shown promising results in preclinical and early clinical trials, with the potential to be used in combination with existing chemotherapy regimens.

2. Combination Therapies

Panbela is also exploring the use of SBP-101 in combination with other therapeutic agents to enhance efficacy and broaden its application to other cancer types. This includes ongoing research into its potential use in treating ovarian cancer, colorectal cancer, and other malignancies.

3. Research and Development (R&D)

The company invests heavily in R&D to expand its pipeline of innovative therapies. Panbela collaborates with academic institutions and research organizations to explore new indications for its products and to identify additional drug candidates.

Business Model

Panbela Therapeutics operates as a clinical-stage biopharmaceutical company, meaning its primary focus is on the research, development, and clinical testing of its drug candidates. The company generates revenue through partnerships, licensing agreements, and potential future sales of its approved products. Panbela’s business model is built around:

  • Innovation: Developing first-in-class and best-in-class therapies for cancer treatment.
  • Collaboration: Partnering with academic institutions, research organizations, and pharmaceutical companies to accelerate drug development.
  • Regulatory Milestones: Achieving key regulatory approvals to advance its drug candidates through clinical trials and toward commercialization.

Strategic Direction

Panbela Therapeutics is committed to advancing its pipeline of oncology therapies and expanding its market presence. Key strategic priorities include:

  • Pipeline Expansion: Continuing to develop SBP-101 for additional cancer indications and exploring new drug candidates.
  • Clinical Trials: Advancing SBP-101 through Phase II and Phase III clinical trials to demonstrate safety and efficacy.
  • Global Reach: Expanding its presence in international markets through partnerships and licensing agreements.
  • Sustainability Goals: Incorporating sustainable practices into its operations, including reducing waste and optimizing resource use in clinical trials.
  • Innovation: Leveraging cutting-edge research to identify new therapeutic targets and develop novel treatments.

Competitive Landscape

Panbela Therapeutics operates in a highly competitive oncology market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Eli Lilly and Company: Known for its oncology portfolio, including drugs like Gemzar (gemcitabine) for pancreatic cancer.
  • Bristol-Myers Squibb: A leader in immuno-oncology with products like Opdivo (nivolumab).
  • AstraZeneca: Offers targeted therapies such as Lynparza (olaparib) for ovarian and pancreatic cancers.
  • Other Biotech Firms: Smaller companies developing novel cancer therapies, such as Blueprint Medicines and Mirati Therapeutics.

Panbela differentiates itself through its focus on polyamine metabolic inhibition, a unique approach to cancer treatment.

Risk Factors

Like any clinical-stage biopharmaceutical company, Panbela Therapeutics faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its drug candidates.
  • Clinical Trial Risks: Uncertainty regarding the safety and efficacy of its products in clinical trials.
  • Market Dependence: Reliance on the success of SBP-101 for future revenue generation.
  • Competition: Intense competition from larger pharmaceutical companies with established oncology portfolios.
  • Financial Risks: Limited revenue streams and dependence on external funding to support operations.
  • Supply Chain Disruptions: Potential challenges in sourcing raw materials and manufacturing clinical trial supplies.

Recent Developments

Panbela Therapeutics has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Updates: Positive interim results from ongoing Phase II trials of SBP-101 in combination with standard chemotherapy for pancreatic cancer.
  • Partnerships: Collaboration agreements with leading academic institutions to explore new indications for SBP-101.
  • Corporate Strategy: Strengthening its leadership team with the appointment of experienced executives in oncology drug development.
  • Global Developments: The COVID-19 pandemic has posed challenges to clinical trial enrollment and supply chain logistics, but Panbela has implemented measures to mitigate these impacts.

Investment Considerations

Investors considering Panbela Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: A promising drug candidate (SBP-101) with potential applications in multiple cancer types.
  • Experienced Leadership: A management team with a proven track record in oncology drug development.
  • Market Opportunity: Significant unmet medical needs in pancreatic cancer and other solid tumors.
  • Collaborative Approach: Partnerships with academic institutions and research organizations to accelerate innovation.

Risks

  • Clinical and Regulatory Uncertainty: The success of SBP-101 is not guaranteed, and regulatory approvals are required for commercialization.
  • Financial Dependence: Limited revenue streams and reliance on external funding.
  • Competitive Pressure: Intense competition from established pharmaceutical companies and emerging biotech firms.
  • Market Volatility: The biopharmaceutical sector is subject to market fluctuations and investor sentiment.

Conclusion

Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company with a strong focus on developing innovative therapies for cancer treatment. With its flagship product candidate SBP-101, the company is addressing significant unmet medical needs in oncology. While Panbela faces challenges typical of clinical-stage companies, its innovative pipeline, experienced leadership, and collaborative approach position it for potential success. As the company advances its clinical trials and explores new indications for its products, it remains a compelling player in the oncology market with opportunities for future growth.